VLDLR and metabolic dysfunction-associated steatotic liver disease: Atherosclerosis and NAFLD models were established by treatment of low density lipoprotein receptor-deficient (Ldlr−/−) mice and NLRP3−/− Ldlr−/− mice with a HFD diet (20% fat and 0.5% cholesterol) with or without APN.